医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toshiba Heavy-Ion Therapy System Awarded by Yonsei University Health System

2018年03月29日 PM12:00
このエントリーをはてなブックマークに追加


 

KAWASAKI, Japan

Toshiba Energy Systems & Solutions Corporation (Toshiba ESS), a world leader in heavy-ion therapy system, in collaboration as a consortium with DK Medical Solutions, a Korean leading global medical company, is awarded a contract to supply a heavy-ion therapy system to Yonsei University Health System (YUHS), one of the leading providers of medical services in Korea. This is the first overseas contract of a heavy-ion therapy system for Toshiba ESS.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180328006255/en/

Image of heavy-ion therapy system (Graphic: Business Wire)

Image of heavy-ion therapy system (Graphic: Business Wire)

YUHS was founded in 1885 as the first modernized hospital in Korea. Being one of the most prominent hospitals in Seoul, it has been taking in various kinds of the latest and the best medical technologies. YUHS has more than 9,000 outpatients and the radiation oncology department of Yonsei Cancer Center treats more than 350 patients in a day.

The awarded heavy-ion therapy system will be equipped with one horizontally-fixed beam treatment room and two rotating gantry treatment rooms. Toshiba’s sophisticated leading-edge technologies such as high-speed scanning irradiation devices and superconducting magnets will be incorporated in the system. The heavy-ion therapy facility with two rotating gantry treatment rooms will be the first in the world. The treatment will start in 2022.

Heavy-ion therapy uses particles such as carbon ions to generate a high-energy beam that irradiates cancerous tissues—the system accelerates carbon-ion beam to up to 70% of the speed of light and delivers a concentrated dose of radiation to the targeted part. In addition to being fast and non-invasive, it ensures pinpoint and lethal irradiation to cancerous tissues efficiently, with minimum damage to surrounding healthy tissues, and with fewer fractions compared to other radiotherapies.

Toshiba ESS has been developing heavy-ion therapy systems in collaboration with National Institute for Quantum and Radiological Science and Technology (QST/NIRS) for decades and has made contributions to several heavy-ion facilities in Japan. Highly-advanced technologies such as quick-and-accurate patient positioning, 3D high-speed scanning irradiation, respiratory gating and rotating gantry, have been already utilized in the facilities. Especially, the downsized rotating gantry owing to superconducting magnets and an advanced irradiation nozzle is the key differentiator of Toshiba ESS technology. These front-line achievements have been highly evaluated by Yonsei University Severance Hospital, which has led to the award.

Commenting on the contract with YUHS, Mamoru Hatazawa, vice president of Toshiba ESS said, “Toshiba ESS is highly proud of this contract with Yonsei University Health System, which is the most prestigious hospital in Korea. Our technologies have been developed in collaboration with QST/NIRS and I am quite confident that our state-of-the-art heavy ion therapy system will contribute to the advanced radiotherapy in YUHS cancer center.”

Do-Heum Yoon, president & CEO of YUHS said, “Heavy-ion therapy, known as the most advanced cancer treatment in the world, will deliver the promise of patient-centered care in an era of incurable cancer and super-aging society.
Through the introduction of Toshiba’s heavy-ion therapy system, YUHS hopes to bring breakthrough innovations in cancer therapy as we did when we opened nation’s first cancer center more than five decades ago.”

Toshiba ESS will use the world-leading performance of the system to expand business in the global market.

Yonsei University Health System
https://www.youtube.com/embed/eTPrK-30uss?rel=0

About Toshiba Energy Systems & Solutions Corporation:
Toshiba Energy Systems & Solutions Corporation is a leading supplier of integrated energy solutions. With its long experience and expertise in wide range of power generating and transmitting systems and energy management technology, the company delivers innovative, reliable and efficient energy solutions across the globe. Split off from Toshiba Corporation (TOKYO: 6502) in October 2017.
https://www.toshiba-energy.com/en/index.htm

View source version on businesswire.com: https://www.businesswire.com/news/home/20180328006255/en/

CONTACT

Press Contact:
Toshiba Corporation Energy Systems &
Solutions Company
Yuu Takase / Tomoyuki Kaku, +81-44-331-7200

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続